Aurélien Marabelle, Medical Oncologist at Gustave Roussy and Professor of Clinical Immunology at Paris-Saclay University, shared a recent article on LinkedIn:
“Subtle differences in antibody engineering can make big impacts on treatment efficacy and patient safety.
Check out our latest review on Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology if you want to learn more.”
Title: Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Authors: Romane Martineau, Sandrine Susini and Aurelien Marabelle
For more updates, follow OncoDaily.